# OnCo record bpx-603 (drug). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/drugs/bpx-603/>
  a schema:Drug ;
  onco:kind "drug" ;
  schema:identifier "bpx-603" ;
  schema:name "BPX-603"@en ;
  schema:description "BPX-603 is an autologous dual-switch CAR-T cell therapy from Bellicum Pharmaceuticals that reached phase 1 for HER2-positive solid tumours, HER2-positive gastric cancer and HER2-positive breast cancer; development has stopped."@en ;
  schema:url <https://onco.cc/drugs/bpx-603/> ;
  schema:dateModified "2026-11-03"^^xsd:date ;
  schema:citation <https://www.sec.gov/Archives/edgar/data/1358403/000162828023010145/blcm-20221231.htm>, <https://www.sec.gov/Archives/edgar/data/1358403/000153949723002188/exh99-1.htm>, <https://clinicaltrials.gov/search?intr=BPX-603> ;
  onco:status "phase-1" ;
  onco:tag "pipeline", "ctgov-ingest", "discontinued" ;
  onco:modality "Autologous dual-switch CAR-T cell therapy (GoCAR platform)" ;
  onco:cancers <https://onco.cc/cancers/metastatic-cancer/>, <https://onco.cc/cancers/gastric-her2-positive/>, <https://onco.cc/cancers/breast-her2-positive/> ;
  onco:targets <https://onco.cc/targets/her2/> ;
  onco:companies <https://onco.cc/companies/bellicum/> ;
  onco:trials <https://onco.cc/trials/nct04650451/> .